Efficacy and safety of concurrent chemoradiation with weekly cisplatin ± low-dose celecoxib in locally advanced undifferentiated nasopharyngeal carcinoma: A phase II-III clinical trial

Journal of Cancer Research and Therapeutics

Volumn 7, Issue 4, 2011, Pages 442-447

  Mohamma Dianpanah, Mohammad ^a   Razmjou Ghalaei, Sasan ^b   Shafizad, Amin ^c   Ashouri Taziani, Yaghoub ^a   Khademi, Bijan ^d,e   Ahmadloo, Niloofar ^a   Ansari, Mansour ^a   Omidvari, Shapour ^a   Mosalaei, Ahmad ^a,e   Mosleh Shirazi, Mohammad Amin ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Department of Radiation Oncology   (Iran)

^d SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Celecoxib; chemotherapy; concurrent chemoradiation; cyclooxygenase 2 (COX 2) inhibitors; locally advanced undifferentiated nasopharyngeal carcinoma; weekly cisplatin

Indexed keywords

CELECOXIB; CISPLATIN; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CHEMORADIOTHERAPY; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENERAL CONDITION IMPROVEMENT; HUMAN; KARNOFSKY PERFORMANCE STATUS; LOCALLY ADVANCED UNDIFFERENTIATED NASOPHARYNGEAL CARCINOMA; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CISPLATIN; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PYRAZOLES; SULFONAMIDES;

EID: 84856454328     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.92013     Document Type: Article

References (31)

1. Agulnik M, Siu LL. State-of-the-art management of nasopharyngeal carcinoma: Current and future directions. Br J Cancer 2005;92:799-806.
2. Afqir S, Ismaili N, Errihani H. Concurrent chemoradiotherapy in the management of advanced nasopharyngeal carcinoma: Current status. J Cancer Res Ther 2009;5:3-7.
3. Alshafie GA, Abou-Issa HM, Seibert K, Harris RE. Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 2000;7:1377-81.
4. Yao M, Zhou W, Sangha S, Albert A, Chang AJ, Liu TC, et al. Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res 2005;11:1618-28.
5. Lee DW, Sung MW, Park SW, Seong WJ, Roh JL, Park B, et al. Increased cyclooxygenase-2 expression in human squamous cell carcinomas of the head and neck and inhibition of proliferation by nonsteroidal anti-inflammatory drugs. Anticancer Res 2002;22:2089-96.
6. Soo RA, Wu J, Aggarwal A, Tao Q, Hsieh W, Putti T, et al. Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression. Ann Oncol 2006;17:1625-30.
7. Lim SC, Park SY, Do NY. Correlation of cyclooxygenase-2 pathway and VEGF expression in head and neck squamous cell carcinoma. Oncol Rep 2003;10:1073-9.
8. Chen PY, Long QC. Effects of cyclooxygenase 2 inhibitors on biological traits of nasopharyngeal carcinoma cells. Acta Pharmacol Sin
9. Ye F, Wu J, Dunn T, Yi J, Tong X, Zhang D. Inhibition of cyclooxygenase-2 activity in head and neck cancer cells by genistein. Cancer Lett 2004;211:39-46.
10. Milas L. Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy. Am J Clin Oncol 2003;26:S66-9.
11. Davis TW, Hunter N, Trifan OC, Milas L, Masferrer JL. COX-2 inhibitors as radiosensitizing agents for cancer therapy. Am J Clin Oncol 2003;26:S58-61.
12. Choy H, Milas L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: A rational advance? J Natl Cancer Inst 2003;95:1440-52.
13. Raju U, Ariga H, Dittmann K, Nakata E, Ang KK, Milas L. Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib. Int J Radiat Oncol Biol Phys 2005;63:520-8.
14. Milas L, Mason KA, Crane CH, Liao Z, Masferrer J. Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme. Oncology (Wilson Park) 2003;17:15-24.
15. Süleyman H, Demircan B, Karagöz Y, Oztaşan N, Süleyman B. Antiinflammatory effects of selective COX-2 inhibitors. Pol J Pharmacol 2004;56:775-80.
16. Herrera FG, Chan P, Doll C, Milosevic M, Oza A, Syed A, et al. A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment. Int J Radiat Oncol Biol Phys 2007;67:97-103.
17. Govindan R, McLeod H, Mantravadi P, Fineberg N, Helft P, Kesler K, et al. Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: Preliminary results. Oncology (Wilson Park) 2004;18:18-21.
18. Tfayli A, Yang J, Kojouri1 K, Kesserwan C, Jafari M, Ozer H. Neoadjuvant therapy with celecoxib to women with early stage breast cancer. Neoplasma 2008;55:122-6.
19. Dirix LY, Ignacio J, Nag S, Bapsy P, Gomez H, Raghunadharao D, et al. Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib. J Clin Oncol 2008;26:53-9.
20. Chow LW, Yip AY, Loo WT, Lam CK, Toi M. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol 2008;111:13-7.
21. Gupta T, Agarwal JP, Ghosh-Laskar S, Parikh PM, D'Cruz AK, Dinshaw KA. Radical radiotherapy with concurrent weekly cisplatin in locoregionally advanced squamous cell carcinoma of the head and neck: A single-institution experience. Head Neck Oncol 2009;1:17.
22. Isobe K, Uno T, Aruga T, Kawakami H, Ueno N, Hanazawa T, et al. Weekly cisplatin administration concurrent with radiation therapy for locoregionally advanced nasopharyngeal carcinoma. Int J Clin Oncol 2005;10:201-3.
23. Park JH, Nam SY, Lee SW, Kim SB, Kim SY, Lee BJ, et al. Radiation therapy with UFT and low dose weekly cisplatin for nasopharyngeal carcinoma. Auris Nasus Larynx 2005;32:43-8.
24. Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 2009;27:242-9.
25. Mohammadianpanah M, Omidvari S, Mosalaei A, Ahmadloo N. Cisplatin-induced hypokalemic paralysis. Clin Ther 2004;26:1320-3.
26. Bae WK, Hwang JE, Shim HJ, Cho SH, Lee JK, Lim SC, et al. Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer. Cancer Chemother Pharmacol 2010;65:589-95.
27. Kao J, Genden EM, Chen CT, Rivera M, Tong CC, Misiukiewicz K, et al. Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer. Cancer 2011;117:3173-81.
28. Rich TA, Shepard R. COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: Esophagus, stomach, and pancreas. Am J Clin Oncol 2003;26:S110-3.
29. Mutter R, Lu B, Carbone DP, Csiki I, Moretti L, Johnson DH, et al. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res 2009;15:2158-65.
30. Gaffney DK, Winter K, Dicker AP, Miller B, Eifel PJ, Ryu J, et al. Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128. Int J Radiat Oncol Biol Phys 2007;69:111-7.
31. Kesari S, Schiff D, Henson JW, Muzikansky A, Gigas DC, Doherty L, et al. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol 2008;10:300-8.